Identification of a novel isoform of iASPP and its interaction with p53.
Explore this paper's citation graph
Summary
It is found that iASPP-SV is a nuclear protein, and is capable of binding to p53 in vivo, and can inhibit the transcriptional activity of p53 on the promoters of both Bax and p21.
- Type
- article
- Published
- 2007-05-11
- Cited by
- 19
- References
- 56
- OpenAlex
- https://openalex.org/W1984321855
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3207306
Keywords
Ankyrin repeat, Gene isoform, Open reading frame, Biology, Molecular biology
References
- PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53
- Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
- Single-shot plasmid DNA intrasplenic immunization for the production of monoclonal antibodies. Persistent expression of DNA.
- The C-terminus of p53: the more you learn the less you know
- In vivo gene expression profile analysis of human breast cancer progression.
- A transcriptionally active DNA-binding site for human p53 protein complexes
- Structural basis for the binding of proline-rich peptides to SH3 domains.
- p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma
- Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response
- p53: 25 years after its discovery.
- The ASPP family: deciding between life and death after DNA damage.
- Downregulated mRNA expression of ASPP and the hypermethylation of the 5′‐untranslated region in cancer cell lines retaining wild‐type p53
- Identification of a novel p53 functional domain that is necessary for efficient growth suppression.
- Identification of an additional negative regulatory region for p53 sequence-specific DNA binding.
- p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.
- Two cellular proteins that bind to wild-type but not mutant p53.
- IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools
- Decision making by p53: life, death and cancer
- Effects of Oncogenic Mutations and DNA Response Elements on the Binding of p53 to p53-binding Protein 2 (53BP2)*
- Identification of a Novel Inhibitor of Nuclear Factor-κB, RelA-associated Inhibitor*
Cited by
- Cooperation of p300 and iASPP in apoptosis and tumour suppression
- iASPP: a novel protein involved in pituitary tumorigenesis?
- A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP
- Construction of a full-length iASPP expression plasmid pcDNA3.1+/iASPP and its biological activity.
- siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.
- iASPP, a potential drug target in cancer therapy.
- iASPPsv antagonizes apoptosis induced by chemotherapeutic agents in MCF-7 cells and mouse thymocytes.
- p53 and PPP1R13L (alias iASPP or RAI) form a feedback loop to regulate genotoxic stress responses.
- Molecular docking analysis of the protein–protein interaction between RelA‐associated inhibitor and tumor suppressor protein p53 and its inhibitory effect on p53 action
- Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis
- iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway
- Oncogene iASPP enhances self‐renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation
- Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis
- MicroRNA-140 regulates cell growth and invasion in pancreatic duct adenocarcinoma by targeting iASPP.
- Original paper The leukemogenic role of (iASPP) in acute leukemia
- Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells
- Targeting an interaction between two disordered domains using a designed peptide.
- Targeting Protein Interaction Hotspots Using Structured and Disordered Chimeric Peptide Inhibitors.
- Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review
- The leukemogenic role of (iASPP) in acute leukemia
Related papers
- Insights into the structure and protein-protein interactions of the pro-apoptotic protein ASPP2.
- Tankyrase-1 Ankyrin Repeats Form an Adaptable Binding Platform for Targets of ADP-Ribose Modification.
- Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.
- Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2
- The ASPP interaction network: electrostatic differentiation between pro‐ and anti‐apoptotic proteins
- Structural domains required for channel function of the mouse transient receptor potential protein homologue TRP1β
- A disordered encounter complex is central to the yeast Abp1p SH3 domain binding pathway
- Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase
- Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein